UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1395-5
Program Prior Authorization/Notification
Medication Zoryve® (roflumilast)
P&T Approval Date 9/2022, 9/2023, 11/2023, 2/2024, 12/2024
Effective Date 3/1/2025
1. Background:
Zoryve (roflumilast) 0.3% cream is a phosphodiesterase 4 inhibitor indicated for topical treatment
of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older. Zoryve
(roflumilast) foam is indicated for the treatment of seborrheic dermatitis in adult and pediatric
patients 9 years of age and older. Zoryve (roflumilast) 0.15% cream is indicated for the topical
treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of
age and older.
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Zoryve 0.3% cream will be approved based upon the following criterion:
(1) Diagnosis of plaque psoriasis
Authorization will be issued for 12 months.
2. Reauthorization
a. Zoryve 0.3% cream will be approved based upon the following criterion:
(1) Documentation of positive clinical response to therapy
Authorization will be issued for 12 months.
B. Seborrheic Dermatitis
1. Initial Authorization
a. Zoryve foam will be approved based upon the following criterion:
(1) Diagnosis of seborrheic dermatitis
Authorization will be issued for 12 months.
2. Reauthorization
© 2024 UnitedHealthcare Services, Inc.
1
a. Zoryve foam will be approved based upon the following criterion:
(1) Documentation of positive clinical response to therapy
Authorization will be issued for 12 months.
C. Atopic Dermatitis
1. Initial Authorization
a. Zoryve 0.15% cream will be approved based upon the following criterion:
(1) Diagnosis of mild to moderate atopic dermatitis
Authorization will be issued for 12 months.
2. Reauthorization
a. Zoryve 0.15% cream will be approved based upon the following criterion:
(1) Documentation of positive clinical response to therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits, Medical Necessity, and/or Step Therapy may be in place.
4. References:
1. Zoryve cream [package insert]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; July
2024.
2. Zoryve foam [package insert]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; December
2023.
Program Prior Authorization/Notification – Zoryve (tapinarof)
Change Control
9/2022 New program.
9/2023 Annual review with no change to clinical criteria.
© 2024 UnitedHealthcare Services, Inc.
2
11/2023 Updated background to include patients 6 years of age and older.
Updated reference.
2/2024 Added criteria for Zoryve foam for seborrheic dermatitis. Updated
background and reference.
12/2024 Added criteria for Zoryve 0.15% cream for atopic dermatitis. Updated
plaque psoriasis criteria to specify 0.3% cream. Updated all
authorizations to 12 months. Updated background and reference.
© 2024 UnitedHealthcare Services, Inc.
3